Therapy
Sjögren’s syndrome: from pathogenesis to novel therapeutic targets.
F. Barone1, S. Colafrancesco2
- Centre for Translational Inflammation Research, Institute of Inflammation and Ageing, University of Birmingham, UK. f.barone@bham.ac.uk
- Centre for Translational In ammation Research, Institute of In ammation and Ageing, University of Birmingham, UK; and Department of Internal Medicine and Medical Specialties, Rheumatology Unit, Sapienza University of Rome, Italy.
CER9740
2016 Vol.34, N°4 ,Suppl.98
PI 0058, PF 0062
Therapy
Free to view
(click on article PDF icon to read the article)
PMID: 27586806 [PubMed]
Received: 07/07/2016
Accepted : 07/07/2016
In Press: 21/07/2016
Published: 03/08/2016
Abstract
Primary Sjögren’s syndrome (pSS) is a chronic inflammatory autoimmune disease, characterised by a chronic infiltration of exocrine glands, mainly salivary glands, with the histological features of focal lymphocytic sialoadenitis. Disease spectrum is broad and the occurrence of several extra-glandular manifestations, and in rare cases lymphoma development, is well known. A specific approved treatment for pSS is still lacking and the detection of novel therapeutic biologic target is ongoing. The identification of biological fingerprints seems essential in order to stratify patients both in clinical trials and in real life. Discovery of new components of the inflammatory response will be the key in the future for the identification of novel additional therapeutic options.
